TY - JOUR
T1 - Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer
AU - Trestini, Ilaria
AU - Caldart, Alberto
AU - Cintoni, Marco
AU - Sperduti, Isabella
AU - Drudi, Alessandro
AU - Aluffi, Gregorio
AU - Fiorio, Elena
AU - Parolin, Veronica
AU - Zambonin, Valentina
AU - Zanelli, Sara
AU - Tregnago, Daniela
AU - Avancini, Alice
AU - Pilotto, Sara
AU - Aprili, Irene
AU - Zandonà, Emanuela
AU - D'Onofrio, Mirko
AU - Mele, Maria Cristina
AU - Gasbarrini, Antonio
AU - Scambia, Giovanni
AU - Tortora, Giampaolo
AU - Milella, Michele
AU - Bria, Emilio
AU - Carbognin, Luisa
PY - 2023
Y1 - 2023
N2 - Objectives: Excess adiposity is associated with several factors involved in carcinogenesis and breast cancer progression. Evidence supporting the role of body composition in breast cancer treatment is promising, but still scanty and mainly focused on adjuvant treatment. The aim of this study was to evaluate the changes in body composition during neoadjuvant chemotherapy and its association with pathologic complete response and survival outcome in patients treated for operablejlocally advanced breast cancer.Methods: A retrospective review of patients with breast cancer treated with neoadjuvant chemotherapy was performed in the Oncology Section of the Department of Medicine, University of Verona between 2014 and 2019. Body composition was evaluated from clinically acquired computed tomography scans at diagnosis and after neoadjuvant chemotherapy. Descriptive statistic was adopted. The associations of body composition measures with pathologic complete response and disease-free survival were analyzed. Kaplan-Meier curves were compared with log-rank analysis.Results: Data from 93 patients were collected. After neoadjuvant chemotherapy, the adipose compound changed significantly across all body mass index categories. Body composition parameters had no significant effect on pathologic complete response. Survival analysis showed that a high gain of visceral adipose tissue during neoadjuvant chemotherapy was associated with shorter disease-free survival (hazard ratio, 10.2; P = 0.026). In particular, disease-free survival was significantly worse in patients who gained >= 10% of visceral adipose tissue compared with patients who gained < 10% of visceral adipose tissue (5-y disease-free survival 71.4 versus 96.3, P = 0.009, respectively).Conclusions: Our results indicated that neoadjuvant chemotherapy significantly affects body composition, which seems to have an effect on survival outcome of breast cancer, highlighting the relevance of the body composition assessment when estimating treatment outcomes. (C) 2022 Elsevier Inc. All rights reserved.
AB - Objectives: Excess adiposity is associated with several factors involved in carcinogenesis and breast cancer progression. Evidence supporting the role of body composition in breast cancer treatment is promising, but still scanty and mainly focused on adjuvant treatment. The aim of this study was to evaluate the changes in body composition during neoadjuvant chemotherapy and its association with pathologic complete response and survival outcome in patients treated for operablejlocally advanced breast cancer.Methods: A retrospective review of patients with breast cancer treated with neoadjuvant chemotherapy was performed in the Oncology Section of the Department of Medicine, University of Verona between 2014 and 2019. Body composition was evaluated from clinically acquired computed tomography scans at diagnosis and after neoadjuvant chemotherapy. Descriptive statistic was adopted. The associations of body composition measures with pathologic complete response and disease-free survival were analyzed. Kaplan-Meier curves were compared with log-rank analysis.Results: Data from 93 patients were collected. After neoadjuvant chemotherapy, the adipose compound changed significantly across all body mass index categories. Body composition parameters had no significant effect on pathologic complete response. Survival analysis showed that a high gain of visceral adipose tissue during neoadjuvant chemotherapy was associated with shorter disease-free survival (hazard ratio, 10.2; P = 0.026). In particular, disease-free survival was significantly worse in patients who gained >= 10% of visceral adipose tissue compared with patients who gained < 10% of visceral adipose tissue (5-y disease-free survival 71.4 versus 96.3, P = 0.009, respectively).Conclusions: Our results indicated that neoadjuvant chemotherapy significantly affects body composition, which seems to have an effect on survival outcome of breast cancer, highlighting the relevance of the body composition assessment when estimating treatment outcomes. (C) 2022 Elsevier Inc. All rights reserved.
KW - Body composition
KW - Breast cancer
KW - Visceral adipose tissue
KW - Survival
KW - Neoadjuvant chemotherapy
KW - Body composition
KW - Breast cancer
KW - Visceral adipose tissue
KW - Survival
KW - Neoadjuvant chemotherapy
UR - http://hdl.handle.net/10807/241415
U2 - 10.1016/j.nut.2022.111858
DO - 10.1016/j.nut.2022.111858
M3 - Article
SN - 0899-9007
VL - 105
SP - 111858-N/A
JO - Nutrition
JF - Nutrition
ER -
